BOSTON, MA, and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) September 30, 2017. BioAegis Therapeutics Inc. announced that founding scientist Dr. Thomas P. Stossel presented the 24th Annual William C. Maloney Lecture on September 28, 2017 in the Bornstein Amphitheater at the Brigham and Women’s Hospital. The invited lecture was entitled, “Can our 10th Most Abundant Plasma Protein (that you’ve never heard of) Prevent Sepsis?”

This lectureship was established in 1991 to honor William C. Moloney, MD, formerly the Director of the Hematology Division at the Brigham and Women’s Hospital.

Thomas P. Stossel, MD, BioAegis Therapeutics’ founding scientist, is the discover of gelsolin. Dr. Stossel is Professor of Medicine Emeritus, Harvard Medical School; American Cancer Society Clinical Research Professor and Senior Physician, Brigham and Women’s Hospital. He is the holder of numerous patents and author of more than 300 papers, studies, and reviews. He is also a member of The National Academy of Sciences, The American Academy of Arts and Sciences, and the National Academy of Medicine, currently the Editor-in-Chief of Current Opinion in Hematology and Past Editor of Journal of Clinical Investigation, Past President of the American Society of Hematology and the American Society of Clinical Investigation.

Dr. Stossel commented, “I am honored to participate in this esteemed lecture series. It is especially gratifying to share with my Harvard colleagues the potential for plasma gelsolin, a protein which has been shown to have the ability to mobilize the body’s immune system to fight infections well as prevent the spread of excess inflammation in settings that often lead to organ failure and ultimately sepsis.”